AnGes, Inc. (4563) Stock Price

AnGes develops and sells pharmaceutical products, with a focus on gene medicines. The company specializes in research and development of gene therapy products and nucleic acid medicines. Additionally, AnGes operates a testing service business that provides screening tests for rare genetic disorders.

EmendoBio Inc., a subsidiary of AnGes, is advancing research and development of genome editing products for diseases that currently have no treatment options. This research is conducted at Emendo Research and Development Ltd., a subsidiary based in Israel.

AnGes USA, Inc., the company's U.S. subsidiary, is responsible for developing gene medicines for the American market. Through this operation, AnGes strengthens its presence in international markets.

AnGes opened AnGes Clinical Research Laboratory in 2021 and provides screening testing services for rare genetic disorders. This service is conducted based on requests from CReARID (the general incorporated association promoting medical care and research for rare diseases).

In pharmaceutical development, revenue is generated through upfront payments, development cooperation fees, milestone payments, and royalties. These payments are received based on contracts with other companies and depend on development progress and post-launch sales figures.

Anges aims to become a global leader in gene medicine by developing new treatments for diseases with no existing cures. The company prioritizes maximizing the value of its HGF gene therapy products and accelerating their commercialization in the United States, with the goal of creating new markets.

The company is actively pursuing global expansion, focusing on drug development and commercialization in the United States and Europe. Beyond HGF gene therapy products, Anges is developing new treatment approaches using genome editing technology.

Deepening and expanding its drug discovery platform is a key strategy. Building on plasmid DNA and nucleic acid foundations, the company aims to achieve efficient gene expression and advance treatment development using genome editing technology. This approach supports pipeline expansion.

Anges is strengthening its focus on rare genetic diseases. Through Anges Clinical Research Laboratory, the company is expanding screening test services and leveraging its testing business to create synergies with pharmaceutical research and development.

Anges reduces development risk through partnerships with other pharmaceutical companies and mitigates financial risk by receiving upfront payments and royalties. This approach strengthens development and commercialization capabilities while supporting sustainable growth.